The emerging problem of linezolid-resistant Staphylococcus.

Link to article at PubMed

The emerging problem of linezolid-resistant Staphylococcus.

J Antimicrob Chemother. 2012 Sep 4;

Authors: Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM


The oxazolidinone antibiotic linezolid has demonstrated potent antimicrobial activity against Gram-positive bacterial pathogens, including methicillin-resistant staphylococci. This article systematically reviews the published literature for reports of linezolid-resistant Staphylococcus (LRS) infections to identify epidemiological, microbiological and clinical features for these infections. Linezolid remains active against >98% of Staphylococcus, with resistance identified in 0.05% of Staphylococcus aureus and 1.4% of coagulase-negative Staphylococcus (CoNS). In all reported cases, patients were treated with linezolid prior to isolation of LRS, with mean times of 20.0?±?47.0 months for S. aureus and 11.0?±?8.0 days for CoNS. The most common mechanisms for linezolid resistance were mutation (G2576T) to the 23S rRNA (63.5% of LRSA and 60.2% of LRCoNS) or the presence of a transmissible cfr ribosomal methyltransferase (54.5% of LRSA and 15.9% of LRCoNS). The emergence of linezolid resistance in Staphylococcus poses significant challenges to the clinical treatment of infections caused by these organisms, and in particular CoNS.

PMID: 22949625 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *